Celox™ PPH for Reaching Haemostasis in Patients With Postpartum Hemorrhage

Inclusion Criteria: * Subject or her legally authorized representative is able to understand and provide consent to participate in the clinical investigation * Female Adult subjects (\>18 years of age). * Diagnosis of PPH with suspected uterine atony placental bed bleeding, placenta accreta or previa within 24 hours after vaginal delivery. * Subjects with coagulation disorders can be included * Minimal Estimated Blood Loss (EBL), to be determined when investigator is ready to have the Celox™ PPH package opened. 500 ml of EBL for vaginal delivery or 1000 ml for caesarean section. * Failed first-line intervention of uterotonics and uterine massage/bimanual compression to stop bleeding. Note: Uterotonic administration may continue concomitant with and post the Celox™ PPH use. * Subjects with PPH of cervical or vaginal origin. Exclusion Criteria: Subjects who present with, uterine rupture or for any other conditions outside of atonic post-partum haemorrhage needing other interventional methods or surgery including uterine artery embolization (UAE). * Pregnancy or incomplete multiple pregnancy * Unresolved uterine inversion. * Current cervical cancer. * Current purulent infection of the vagina, cervix, uterus. * Planned c-section with closed cervix. * Patients requiring trans-abdominal insertion of Celox™ PPH.